Cargando…

Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study

Less than half of patients with chronic diseases, including multiple sclerosis (MS), adhere to their prescribed medications. Treatment selection is essential for patient adherence. The aim of this study was to explore the potential factors influencing nonadherence to disease-modifying therapies (DMT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giedraitiene, N., Taluntiene, V., Kaubrys, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300629/ https://www.ncbi.nlm.nih.gov/pubmed/35859004 http://dx.doi.org/10.1038/s41598-022-16790-3

Ejemplares similares

Cognition During and After Multiple Sclerosis Relapse as Assessed With the Brief International Cognitive Assessment for Multiple Sclerosis
por: Giedraitiene, Natasa, et al.
Publicado: (2018)

Distinctive Pattern of Cognitive Disorders During Multiple Sclerosis Relapse and Recovery Based on Computerized CANTAB Tests
por: Giedraitiene, Natasa, et al.
Publicado: (2019)

The BICAMS Battery for Assessment of Lithuanian-Speaking Multiple Sclerosis Patients: Relationship with Age, Education, Disease Disability, and Duration
por: Giedraitienė, Nataša, et al.
Publicado: (2015)

Impact of autologous HSCT on the quality of life and fatigue in patients with relapsing multiple sclerosis
por: Giedraitiene, N., et al.
Publicado: (2022)

Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation in highly active multiple sclerosis
por: Giedraitiene, N., et al.
Publicado: (2020)

Cognitive Decline in Multiple Sclerosis Is Related to the Progression of Retinal Atrophy and Presence of Oligoclonal Bands: A 5-Year Follow-Up Study
por: Giedraitiene, Natasa, et al.
Publicado: (2021)

Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability
por: Giedraitiene, Natasa, et al.
Publicado: (2015)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
por: McKay, Kyla A, et al.
Publicado: (2016)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Association between multiple sclerosis disease severity and adherence to disease-modifying therapies
por: Burkhard, Adam, et al.
Publicado: (2021)

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
por: Zanga, Gisela, et al.
Publicado: (2021)

Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
por: Alosaimi, Fahad D, et al.
Publicado: (2017)

Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
por: Kizlaitienandedot, Rasa, et al.
Publicado: (2017)

The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis
por: Rabadi, Meheroz H, et al.
Publicado: (2021)

Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
por: Washington, Francesca, et al.
Publicado: (2021)

The Relationship between Psychosocial Factors and Cognition in Multiple Sclerosis
por: Alosaimi, Fahad D., et al.
Publicado: (2017)

Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
por: Menzin, Joseph, et al.
Publicado: (2013)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis—Cross-Sectional Study
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2022)

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
por: Morillo Verdugo, Ramón, et al.
Publicado: (2019)

The Relationship between Cognitive Dysfunction and Postural Stability in Multiple Sclerosis
por: Redlicka, Justyna, et al.
Publicado: (2021)

The relationship between cognition, education, and employment in multiple sclerosis patients
por: Conway, Devon S, et al.
Publicado: (2022)

Adherence to Therapy in Patients with Multiple Sclerosis—Review
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2022)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Impact of Adherence with Disease-Modifying Therapies on All-Cause Mortality Rates Among Veterans with Multiple Sclerosis
por: Rabadi, Meheroz H., et al.
Publicado: (2022)

The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis
por: Tarrants, M., et al.
Publicado: (2011)

Use of an Early Disease-Modifying Drug Adherence Measure to Predict Future Adherence in Patients with Multiple Sclerosis
por: Kozma, Chris M., et al.
Publicado: (2014)

Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation
por: Matias-Guiu, Jordi A., et al.
Publicado: (2017)

The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study
por: Lenz, Florian, et al.
Publicado: (2020)

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
por: Beer, Karsten, et al.
Publicado: (2011)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Evaluating the relationship between emotional intelligence and cognitive disorders in patients with Multiple Sclerosis
por: Owji, Mahsa, et al.
Publicado: (2018)

Evaluating the relationship between psychometric intelligence and cognitive functions in paediatric multiple sclerosis
por: Kapanci, Tugba, et al.
Publicado: (2019)

The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study
por: Klein, Ana, et al.
Publicado: (2023)

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
por: Patti, Francesco
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ditc4io7fsqmve4v7o415p3htb